

Media Release



22 July 2009

FOR IMMEDIATE RELEASE

International conference highlights investment potential of biotechnology in the Asia Pac region

Australia's national body for the biotechnology and life sciences industry, AusBiotech, today announced *AusBiotech 2009* - the premier Australasian biotechnology conference, which will focus on highlighting investment opportunities in the Asia Pacific region.

The event will commence with the inaugural *Australasian Life Sciences Investment Summit*, a one-day invitation-only event for investors on 27 October 2009.

The conference will showcase biotechnology research and development from companies across the region, highlighting to representatives of biotech, investment and pharmaceutical sectors from around the world the high calibre of investment potential.

"The Asia-Pacific region has a strong history of producing world leading science and research. Australia in particular is regarded highly as a world-class location for conducting clinical trials," said Dr Anna Lavelle, CEO of AusBiotech.

"We have gathered high-profile figures from the international biotech, investment and pharmaceutical communities to offer an insight into the current state of the sector and the opportunities for investment in local R&D," Dr Lavelle continued.

Following the success of last year's conference which attracted over 1,300 delegates from 32 countries, *AusBiotech 2009* will be held in Melbourne from 27 -30 October 2009 and will feature a comprehensive four-day program. The program will provide four biotechnology streams: human health; medical technology; agriculture, industrial and food; and investment and business.

Further information and interviews:
Lorraine Chiroiu, Media and Communications Manager
P: +61 3 9828 1414
M: +61 429 801 118
E: lchiroiu@ausbiotech.org

Media Release



The event includes the *BioIndustry Exhibition* which provides a showcase of businesses and products in a specially designed exhibition area, and the *Business Matching Program* that matches delegates in a bio-partnering system, offering ideal networking opportunities. Last year 2,608 meeting requests led to 1,226 confirmed meetings through the program.

The conference presentations cover a range of issues relevant to the biotechnology and investment community. Some of the topics to be covered include: Biopharmaceuticals in a Post-GFC World; Global Regulatory Challenges and Opportunities; Product Development and Regulatory Aspects in Asia Pacific; and Changing Business Models and New Financial Opportunities and Health Technologies.

Both international and local companies will be well represented at the conference including CSL; Baxter Healthcare; ABN AMRO Morgans; Biota Holdings; Merck Sharp and Dohme; Roche; J.P Morgans; and Wyeth Pharmaceuticals.

“This is a must-attend event for individuals and companies who wish to engage with the Australasian biotechnology industry and network with representatives from multinational organisations and investors in the region. Delegates at the conference will experience first-hand the enormous investment potential in the region,” said Dr Lavelle.

For additional event information visit the Summit website www.ausbiotech2009.com.au/alsis or the Conference website at: www.ausbiotech2009.com.au/

ENDS

About AusBiotech

AusBiotech is Australia’s voice on biotechnology, and represents more than 3,000 members, encompassing medicines, medical diagnostics and devices, agriculture, alternative fuels and climate change.

Further information and interviews:
Lorraine Chiroiu, Media and Communications Manager
P: +61 3 9828 1414
M: +61 429 801 118
E: lchiroiu@ausbiotech.org